A U.S. government scientist who oversees the team responsible for collecting data on COVID-19 and RSV hospitalizations used ...

The U.S. Centers for Disease Control and Prevention panel of vaccine experts will vote on shots for respiratory syncytial ...

Kennedy Jr. in the country's top health position, use of a long-approved vaccine against measles, mumps, rubella, and ...

Fiona Havers, who oversaw CDC respiratory virus data, told colleagues she no longer had confidence the data would be used objectively to set vaccine policy.

Dr. Fiona Havers, who studied medicine at the University of Washington, says the wholesale dismissal of the CDC's scientific ...

Dr Havers’ departure comes just days after US Health and Human Services (HHS) Secretary Robert F. Kennedy Jr removed all members of the CDC’s Advisory Committee on Immunization Practices (ACIP) and ...

A newly posted agenda for next week’s meeting of the just-appointed group of outside vaccine advisers to the US Centers for ...

A scientist in charge of Covid-19 and respiratory syncytial virus data has abruptly resigned, telling colleagues she doesn’t ...

A Centers for Disease Control and Prevention official who led the agency's network to study hospitalization trends from ...

Havers said in her email that the COVID and RSV data collected by her team had been used in more than 20 peer-reviewed manuscripts and 15 Morbidity and Mortality Weekly Reports issued by the CDC.

The FDA has approved clesrovimab, marketed as Enflonsia, for the prevention of RSV lower respiratory tract disease in ...

vaccine effectiveness from October 2023 to March 2024 against RSV-associated hospitalization reached 75% (95% CI 50-87), according to researchers led by Diya Surie, MD, of the CDC in Atlanta.